“Pharmaceutical company struggling with its obesity drug pipeline and generic competition.”

“Pharmaceutical company discussed regarding its drug Ibrance and its lack of proven survival benefits.”

“Pharmaceutical company discussed for its weak sales forecast and stock decline.”

“Drugmaker discussed for forecasting low sales growth and stock decline.”

“Pharmaceutical company forecasting flat sales for 2026 amid fading COVID-19 shot demand.”